维拉帕米联合化疗药物在恶性肿瘤腹腔化疗中安全性观察  

Security observation of intraperitoneal chemotherapy combined with verapamil in abdominal malignancy

作　　者：杨玲[1] 武军[1] 段巧虹[1] 胡成文[2] 范平生[1] 

机构地区：[1]安徽省肿瘤医院肿瘤内科,安徽合肥230031 [2]安徽省肿瘤医院护理部,安徽合肥230031

出　　处：《安徽医药》2012年第10期1498-1499,共2页Anhui Medical and Pharmaceutical Journal

摘　　要：目的观察及评估维拉帕米联合化疗药物在恶性肿瘤腹腔化疗中安全性。方法收集57例腹腔恶性肿瘤患者临床资料,分别记录腹腔灌注化疗前5 min、化疗后30 min、60 min患者的生命体征变化,记录患者腹腔化疗后药物不良反应,并采用SPSS 13.0统计软件,计量资料采用方差分析。结果 57例患者无一例出现过敏、严重恶心呕吐等不良反应,腹腔化疗前后患者生命体征变化均无显著性差异。结论维拉帕米联合化疗药物的腹腔灌注化疗是安全有效的,可以在恶性腹腔肿瘤患者中推广及应用。Objective To observe and evaluate the intraperitoneal chemotherapy security of verapamil combined with chemotherapy in abdominal malignancy.Methods We collected the clinical data of 57 patients with abdominal malignancy,and recorded the patients＇vital signs and adverse drug reactions at five minutes before intraperitoneal chemotherapy,30 minutes,60 minutes after intraperitoneal chemotherapy.SPSS 13.0 statistical software was used to analyse measurement data.Results There was no case of allergy.Severe nausea,vomiting and other adverse reactions were found in these 57 patients.There was no significant statistical difference in patients＇vital signs between before and after intraperitoneal chemotherapy.Conclusion Intraperitoneal chemotherapy with verapamil is safe and effective,which might be applied in patients with abdominal malignancy.

关 键 词：维拉帕米 腹腔化疗 肿瘤 不良反应 

分 类 号：R730.5[医药卫生—肿瘤]